Firms

IQ Capital

London, GB

iqcapital.vc

signal.nfx.com

goldi.ai

IQ Capital is a dedicated European deep tech venture capital firm, built on the conviction that frontier technology will underpin the next generation of globally significant companies. The firm leads rounds at pre-Seed to Series A and, through its growth opportunity funds, can follow-on with up to $40m per company. Founded in Cambridge in 2007, IQ Capital now operates from London with additional offices in Cambridge and Amsterdam.

Founded: —
Type: Venture capital

Funds3

Fund V2026-01-202026-01-20—
Newer verified vehicle; up to GBP50m cornerstone LP commitment is not total fund size/target/final close. Unsubstantiated USD400m target excluded.
Second Growth Fund2023-06-292023-06-29—
Launched USD200m vehicle alongside Fund IV; final close independently unverified, amount kept null.
Venture Fund IV2023-06-292023-06-29$200M
USD200m final close; official page publication29June2023, earlier reporting5June2023. Not combined USD400m headline.

Team

Investments

team@apexlogos.ai3 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities. Fund size and status | Vehicle/metric | Supported amount/status | Evidence and date | |---|---|---| | Venture Fund IV | **US$200m final close** | [IQ Capital announcement](https://www.iqcapital.vc/news/iq-capital-raises-400m-to-invest-in-transformative-deep-tech-companies), published 2023-06-29. | | Second Growth Fund | **US$200m launched** alongside Fund IV | Same official announcement, 2023-06-29. Wording establishes launch, not an independently documented final close. The headline's $400m combines two vehicles. | | Fund V | **Up to £50m cornerstone LP commitment** by British Business Bank; total fund size/target and final close not verified | [British Business Bank announcement](https://www.british-business-bank.co.uk/news-and-events/news/british-business-bank-makes-ps50-million-cornerstone-commitment-iq-capital-fund-v-back-deeptech), 2026-01-20. This is an LP commitment, not Fund V's total size. | | Firm AUM | US$1bn reported in 2023; £1bn quoted by managing partner in 2026 | The two official announcements above. Different currency/date reporting; do not merge into a single fund size or calculate growth from them. | | Follow-on capacity | Up to **US$40m** through growth opportunity funds | [Official homepage](https://www.iqcapital.vc/), undated, accessed 2026-10-06. Capacity is not a normal initial check, guaranteed allocation or fund size. | [TechCrunch's contemporaneous Fund IV report](https://techcrunch.com/2023/06/05/as-deeptech-and-ai-explodes-european-deeptech-vc-iq-capital-closes-new-200m-fund/), dated 2023-06-05, corroborates the $200m close. Its publication precedes the official site's 2023-06-29 posting: preserve the distinction between report date and official page date. Newer fund searches identified Fund V, so Fund IV must not be called the latest fund. A [Pitchkit profile](https://pitchkit.net/investors/iq-capital), undated/accessed 2026-10-06, claims a $400m Fund V raising target without substantiating primary evidence visible here. Do not adopt that amount pending an official fund document. Latest-known verified final-close amount in the checked sources is Fund IV's $200m, while Fund V is the newer verified vehicle. Funds recorded in Adex after this review: | Fund | Disclosed amount | Announcement / filing date | | --- | --- | --- | | Second Growth Fund | Undisclosed / unverified | 2023-06-29 | | Venture Fund IV | USD 200000000 | 2023-06-29 | | Fund V | Undisclosed / unverified | 2026-01-20 |
team@apexlogos.ai4 hours ago
Match research 2026-10-06 / IQCapital / sha256:a5b73ab03d0523c1dc9cd7fffa8f693decd664c5ec13fd3ba626bc00ed5b8a87 / part 2 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. **Neurovalens — direct neurotechnology.** Non-invasive electrical vestibular-nerve stimulation devices make this a direct neuromodulation example, beyond a generic mental-health app. [IQ's official portfolio profile](https://www.iqcapital.vc/company/neurovalens), undated/accessed 2026-10-06, identifies Neurovalens, labels its investment stage Seed, and describes the nerve-stimulation technology. Its rendering also includes “exited,” without exit explanation. Separately, [Neurovalens' official announcement](https://neurovalens.com/nv_news/neurovalens-secures-6m-investment-in-funding-round-led-by-investment-fund-for-northern-ireland/), **2025-08-19**, confirms a closed **£6m round** and explicit follow-on participation by existing investor IQ Capital. The round was led by IFNI/Clarendon, not IQ. No named series or IQ check amount is given. That 2025 participation means the portfolio's unexplained “exited” tag cannot be used to infer an earlier full exit. Device regulatory statements are issuer claims; this research verifies investor attribution, not clinical efficacy or every clearance. **AiM Medical Robotics — neurosurgical robotics/neurotechnology enabling hardware.** [Company seed announcement](https://www.aimmedicalrobotics.com/aim-medical-robotics-raises-3-4m-in-seed-financing-to-advance-neurosurgery-with-mri-compatible-robotics/), **2022-03-15**, confirms **US$3.4m seed**, led by IQ Capital and Surrey Capital Partners. [Company-issued GlobeNewswire announcement](https://www.globenewswire.com/news-release/2025/09/30/3158877/0/en/AiM-Medical-Robotics-Secures-8-1-Million-Series-A-Financing-to-Transform-Neurosurgery-with-MRI-Compatible-Surgical-Robotics.html), **2025-09-30**, confirms **US$8.1m Series A**, co-led by IQ and **1540 Ventures**. Initial close was June 2025; $3.75m of the total was converted notes. Its MRI-compatible robot guides intracranial procedures and neurostimulation leads for Parkinson's disease. This is brain-surgery/DBS-enabling hardware, not a claim that AiM itself supplies a neural decoder or stimulation implant. The release describes development toward first-in-human studies, not established clinical efficacy. **Opteran — neuroscience-inspired AI, not a direct human neural interface.** Its brain-inspired algorithms justify a separate adjacent classification. Do not conflate reverse-engineering insect behavior with recording or stimulating a patient's nervous system. **BioBeats** and **Closed Loop Medicine** appear in [IQ's official portfolio directory](https://www.iqcapital.vc/companies), undated/accessed 2026-10-06, as biometric preventative health and digital therapies respectively; directory attribution does not establish direct neurotechnology, so they are not counted as additional verified direct neurotech investments here. ## Conflicts, gaps and concrete Adex review notes 1. **Founding year:** saved Adex description and 2023 firm release say 2007; current homepage and 2026 Bank release refer to 2005, and the Bank traces Fund I support to 2006. Firm origins, first fund and legal incorporation may be different milestones. Do not overwrite with one year without clarifying the field's meaning. 2. **Fund distinctions:** add dated Fund IV final close separately from Growth Fund launch, Fund V LP commitment and AUM. Fund V total size, target and final close remain unverified. 3. **Check fields:** $40m is growth follow-on capacity. Keep initial check minimum/sweet spot unknown absent firm evidence; do not populate them from database estimates. 4. **Neurotech:** retain firm attribution for Neurovalens and AiM; add verified dated rounds with correct leads. Explain AiM's surgery-enabling classification and Opteran's adjacent neuromorphic AI classification. 5. **Status:** Neurovalens and Opteran profile “exited” tags lack dates or transaction explanation; confirm before changing ownership/status. Neurovalens' 2025 follow-on is directly documented. 6. **Snapshot hygiene:** review duplicate company IDs/names before adding participations. Snapshot IMU Biosciences entries use the same $53m source with different dates; Porotech has a 2021 entry pointing to a 2022 release. These were observed baseline issues, not fully adjudicated in this focused research. All other snapshot rounds, including newer 2026 leads, remain individually unverified unless discussed above. 7. **NFX geography/team:** do not copy the apparent Massachusetts error or assume accessible Signal team omissions represent actual departures. Current official team and role dates need dedicated review if updating people records. All linked sources were accessed 2026-10-06. Official/issuer evidence establishes public claims and investment participation, not independently audited performance. This is a substantive, selective portfolio review rather than an exhaustive audit of every historic IQ investment.
team@apexlogos.ai4 hours ago
Match research 2026-10-06 / IQCapital / sha256:a5b73ab03d0523c1dc9cd7fffa8f693decd664c5ec13fd3ba626bc00ed5b8a87 / part 1 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. # IQ Capital - Exact Adex ID: `IQCapital` - Canonical Adex URL: https://adex.page/firms/IQCapital - Official website: https://www.iqcapital.vc/ - Research completed/access date: 2026-10-06 - Scope: research for later Adex review; no database changes. IQ Capital is a European deep-tech venture investor with a documented early-stage mandate, dedicated growth follow-on capacity, and verified investments in batteries, quantum networking, semiconductors and neurotechnology. Neurovalens is a direct neurostimulation investment; AiM Medical Robotics is a neurosurgical robotics investment supporting stimulation-lead placement. These are firm investments, not investments inferred from partners' previous employment. ## Starting evidence: Adex and NFX Signal The exact-ID snapshot `data/research/_sources/IQCapital.adex.json` was retrieved on 2026-10-06 from read-only MCP Search. Its record describes pre-seed–Series A leadership and follow-ons up to $40m, London/Cambridge/Amsterdam operations and a 2007 founding. Investor check minimum, maximum and sweet spot are null. Investment entries include Nyobolt, Nu Quantum, Cambridge GaN Devices, Neurovalens, AiM Medical Robotics, BioBeats, Closed Loop Medicine and many others. These are starting claims, not independent verification. The snapshot includes duplicate company representations (Quantum Diamonds/QUANTUMDIAMONDS GMBH, Tropic/Tropic Biosciences, Vsim/Vsim Technology), unknown dates and conflicting date/amount entries. [NFX Signal firm profile](https://signal.nfx.com/firms/iq-capital) was directly accessed on 2026-10-06. The accessible rendering showed the firm name and location “Cambridge, Massachusetts • London • United Kingdom,” but no populated team or stage/check details. Its Massachusetts geography appears inconsistent with official UK identity and should not be imported. The saved Adex source also cites [Signal's DeepTech pre-seed list](https://signal.nfx.com/investor-lists/top-deeptech-pre-seed-investors) as historical acquisition provenance; that list was not independently revalidated here. Signal accessibility does not independently establish investment attribution. ## Fund size and status | Vehicle/metric | Supported amount/status | Evidence and date | |---|---|---| | Venture Fund IV | **US$200m final close** | [IQ Capital announcement](https://www.iqcapital.vc/news/iq-capital-raises-400m-to-invest-in-transformative-deep-tech-companies), published 2023-06-29. | | Second Growth Fund | **US$200m launched** alongside Fund IV | Same official announcement, 2023-06-29. Wording establishes launch, not an independently documented final close. The headline's $400m combines two vehicles. | | Fund V | **Up to £50m cornerstone LP commitment** by British Business Bank; total fund size/target and final close not verified | [British Business Bank announcement](https://www.british-business-bank.co.uk/news-and-events/news/british-business-bank-makes-ps50-million-cornerstone-commitment-iq-capital-fund-v-back-deeptech), 2026-01-20. This is an LP commitment, not Fund V's total size. | | Firm AUM | US$1bn reported in 2023; £1bn quoted by managing partner in 2026 | The two official announcements above. Different currency/date reporting; do not merge into a single fund size or calculate growth from them. | | Follow-on capacity | Up to **US$40m** through growth opportunity funds | [Official homepage](https://www.iqcapital.vc/), undated, accessed 2026-10-06. Capacity is not a normal initial check, guaranteed allocation or fund size. | [TechCrunch's contemporaneous Fund IV report](https://techcrunch.com/2023/06/05/as-deeptech-and-ai-explodes-european-deeptech-vc-iq-capital-closes-new-200m-fund/), dated 2023-06-05, corroborates the $200m close. Its publication precedes the official site's 2023-06-29 posting: preserve the distinction between report date and official page date. Newer fund searches identified Fund V, so Fund IV must not be called the latest fund. A [Pitchkit profile](https://pitchkit.net/investors/iq-capital), undated/accessed 2026-10-06, claims a $400m Fund V raising target without substantiating primary evidence visible here. Do not adopt that amount pending an official fund document. Latest-known verified final-close amount in the checked sources is Fund IV's $200m, while Fund V is the newer verified vehicle. ## Investment stages and mandate The [official homepage](https://www.iqcapital.vc/), accessed 2026-10-06, says IQ leads **pre-seed through Series A**, then supports companies through growth funds. The [2026 Bank release](https://www.british-business-bank.co.uk/news-and-events/news/british-business-bank-makes-ps50-million-cornerstone-commitment-iq-capital-fund-v-back-deeptech) describes Fund V continuing early-stage investing across AI/automation, computing/semiconductors, health/bio, advanced engineering/energy, and security/resilience. Historical Series C participation below demonstrates follow-on activity rather than a blanket late-stage initial-investment mandate. No verified universal initial check range was established. ## Named previous deep-tech investments Amounts below describe company rounds, not IQ Capital's individual contribution. Technology classifications are research assessments based on the cited technical descriptions. | Company | Technology and firm attribution | Round/date and source | |---|---|---| | **Nyobolt** | Proprietary battery anode/cell chemistry and high-power fast charging; IQ Capital and Latitude led the financing. Strong physical-science deep-tech example. | **US$30m**, announced **2025-04-16**; stage not specified in this company release. [Nyobolt official announcement](https://nyobolt.com/resources/news/nyobolt-raises-30-million-as-demand-for-high-power-energy-solutions-surge-with-ai-growth/). | | **Nu Quantum** | Quantum networking connects quantum processors through entanglement infrastructure. IQ Capital explicitly named as a continuing investor; National Grid Partners led. | **US$60m Series A**, closed/announced **2025-12-10**. [Company release](https://www.nu-quantum.com/news/nu-quantum-raises-60m-series-a-in-largest-financing-round-for-quantum-computer-networking). | | **Cambridge GaN Devices** | Gallium nitride power transistors; IQ participated alongside other investors. Materials/semiconductor innovation, rather than ordinary software. | **US$19m Series B**, **2022-11-15**. [Co-investor Cambridge Innovation Capital release](https://www.cic.vc/cic-invests-in-cambridge-gan-devices-19m-series-b-round-to-tackle-the-50b-global-power-semiconductor-market/). A further **US$32m Series C**, **2025-02-18**, names IQ as an existing investor participating; [CIC-issued release reproduced by Publicnow](https://ebs.publicnow.com/view/F4D391419792E06620CA84AD581536A4177F76C5). The latter is an attributed primary issuer statement hosted by an aggregator. | | **DreamFold** | Generative models for therapeutic protein properties: computational biology. IQ's own release identifies it as a Fund IV investment. | Investment already made by **2023-06-29**; round date, stage, size and IQ contribution undisclosed in [official Fund IV release](https://www.iqcapital.vc/news/iq-capital-raises-400m-to-invest-in-transformative-deep-tech-companies). | | **Secretarium** | Confidential computing built around advanced cryptography; IQ's Fund IV announcement explicitly identifies an investment. Technical infrastructure example; classification depends on cryptographic R&D, not simply cloud software. | Investment already made by **2023-06-29**; round details not specified. [Official Fund IV release](https://www.iqcapital.vc/news/iq-capital-raises-400m-to-invest-in-transformative-deep-tech-companies). | | **Opteran** | Insect-brain-inspired autonomous-machine models; clearly technical robotics/neuromorphic AI. Official firm portfolio attribution. | Official profile labels **Series A**, but provides no investment date/amount: [IQ company profile](https://www.iqcapital.vc/company/opteran), undated/accessed 2026-10-06. Profile rendering also includes “exited”; exit date/status requires confirmation. | Neurovalens and AiM below are additional deep-tech medical hardware investments. Ordinary banking, spend-management or security SaaS portfolio entries are not automatically classified as deep tech here merely because IQ uses that umbrella. ## Named previous neurotech investments
team@apexlogos.ai22 days ago
MATCH

Chris Magazzeni IQ Capital, Investor	$10M$700K – $20M	London
Marek Chalupnik IQ Capital, principal	$7M$700K – $13M	Cambridge, Massachusetts
George Glatz IQ Capital, Principal	$7M$700K – $13M	London
Archie Muirhead IQ Capital, analyst	$7M$700K – $13M	United Kingdom
Max Bautin IQ Capital, managing_partner	$3M$500K – $15M	Zurich
Alex Wilson IQ Capital, partner	$1M$100K – $5M	United Kingdom
Richard Little IQ Capital, advisor	$25K$5K – $50K	United Kingdom
Catherine Knott IQ Capital, Investor	—— – —
Conor McCarthy IQ Capital, Investor	—— – —
Céline Caraffa IQ Capital, Investor	—— – —
Ed Stacey IQ Capital, Investor	—— – —
Elaine Hegarty IQ Capital, Investor	—— – —
Jonno Evans IQ Capital, Investor	—— – —
Jordan Billiald IQ Capital, Investor	—— – —
Kerry Baldwin IQ Capital, Investor	—— – —
Kush Desai IQ Capital, Investor	—— – —
Lucy Edwards IQ Capital, Investor	—— – —
Lucy Marston IQ Capital, Investor	—— – —
Mason Sinclair IQ Capital, Investor	—— – —
Naoki Kamimaeda IQ Capital, Investor	—— – —
Ryan Stevens IQ Capital, Investor	—— – —
Simon Hirtzel IQ Capital, Investor	—— – —

$30M2026-08-17	Mindgard	IQ Capital, Lakestar
€15M2026-07-09	Quantum Diamonds	Earlybird Venture Capital, IQ Capital
$53M2026-06-02	IMU Biosciences	IQ Capital
$105M2026-03-13	Tropic	IQ Capital
$50M2026-03-09	Isembard	CIV, IQ Capital, Notion Capital
$220M2026-01-30	VulcanForms	Eclipse, IQ Capital, Greg Reichow, Lior Susan
$60M2025-12-10	Nu Quantum	Amadeus Capital Partners, IQ Capital
$23M2025-11-28	Gravis Robotics	IQ Capital, Pear VC
$—2025-10-06	Trogenix	IQ Capital
$8M2025-09-30	AiM Medical Robotics	IQ Capital, Angular Ventures
$—2025-09-24	Synthesized	Redalpine, IQ Capital
$—2025-09-23	Dalton	Redalpine, IQ Capital
£6M2025-08-19	Neurovalens	IQ Capital
$—2025-06-02	Accelercomm	Bosch Ventures, IP Group, IQ Capital
$30M2025-04-16	Nyobolt	IQ Capital
$10M2025-03-05	Alpine Eagle	General Catalyst, HCVC, IQ Capital
$32M2025-02-18	Cambridge GaN Devices	IQ Capital, Ian Lane
$17M2025-02-05	IONATE	AlbionVC, IQ Capital, David Grimm
$4M2024-11-26	Molyon	IQ Capital, Plural
$12M2024-09-10	NanoSyrinx	IQ Capital
$—2024-03-07	Wobble Genomics	IQ Capital
$53M2024-01-24	IMU Biosciences	IQ Capital
$8M2024	Mindgard	IQ Capital, Lakestar
$—2023-11-30	Mytos	IQ Capital, Wing Venture Capital
$8M2023-11-27	Quantum Diamonds	Earlybird Venture Capital, IQ Capital, Philipp Semmer
$—2023-11-03	Nu Quantum	Seraphim Space, Expeditions, IQ Capital, Amadeus Capital Partners, Cambridge Enterprise, National Security Strategic Investment Fund
$8M2023-10-19	Ai Build	IQ Capital
$—2023-05-25	Signaloid	IQ Capital
$3M2023-05-10	Odin	IQ Capital
$65M2023-03-06	Congruence Therapeutics	IQ Capital
$15M2023-02-23	CyberSmart	IQ Capital
$26M2023-02-01	Risilience	IQ Capital
$19M2022-11-15	Cambridge GaN Devices	Ian Lane, IQ Capital
$—2022-11-09	TOffeeAM	IQ Capital
$14M2022-09-27	Optellum	IQ Capital
$62M2022-06-28	Speechmatics	AlbionVC, IQ Capital
$12M2022-06-23	Opteran	Seraphim Space, IQ Capital, Episode 1, Northern Gritstone
$28M2022-06-09	CybSafe	IQ Capital
$1M2022-03-15	Boltzbit	Speedinvest, IQ Capital
$3M2022-03-15	AiM Medical Robotics	IQ Capital
$20M2022-02-22	Porotech	IQ Capital, Speedinvest
$45M2022-01-28	causaLens	IQ Capital
$—2022	Pictura Bio	IQ Capital
$200M2021-11-29	Thought Machine	BACKED VC, IQ Capital
$8M2021-10-21	Risilience	IQ Capital
$10M2021-06-29	Virti	IQ Capital
$30M2021-06-02	Divido	IQ Capital
$7M2021-01-28	CybSafe	IQ Capital
$2M2020-03-10	Synthesized	IQ Capital
$6M2020	Concirrus	AlbionVC, IQ Capital
$80M2020	Privitar	Accel, IQ Capital
$172M2019-11-06	Coveo	IQ Capital
$—2019-10-21	Speechmatics	AlbionVC, IQ Capital
$12M2019	Audio Analytic	IQ Capital
$1M2018-11-22	Wluper LTD.	IQ Capital
$—2017	Closed Loop Medicine	IQ Capital
$—2015	Audio Analytic	IQ Capital
$5M2014	Audio Analytic	IQ Capital
$—2011	Neul	IQ Capital
$34MUnknown date	Rivan	IQ Capital
$—Unknown date	Oxdx	IQ Capital
$—Unknown date	Oxford Space Systems	IQ Capital
$—Unknown date	Closed Loop Medicine	IQ Capital
$—Unknown date	Dreamfold	IQ Capital
$5MUnknown date	Imperagen	IQ Capital
$—Unknown date	Nuclear Turbines	IQ Capital
$—Unknown date	ToffeeX	IQ Capital
$5MUnknown date	FNA	IQ Capital
$—Unknown date	mQube	IQ Capital
$—Unknown date	mQube	IQ Capital
$—Unknown date	Omegga	IQ Capital
$—Unknown date	Tagomics	IQ Capital
$—Unknown date	Senseye	IQ Capital
$11MUnknown date	Baseimmune	IQ Capital
$2MUnknown date	Neurovalens	IQ Capital
$15MUnknown date	Turintech	IQ Capital
€15M2026-07-09	QUANTUMDIAMONDS GMBH	Earlybird Venture Capital, IQ Capital
$105M2026-03-12	Tropic Biosciences	IQ Capital
$—2026	QUANTUMDIAMONDS GMBH	Earlybird Venture Capital, IQ Capital
$21M2024-09-25	Vsim Technology	IQ Capital
$—2022-11-07	Worldr	IQ Capital
$5M2018-04-10	Spectral Edge	IQ Capital
$3M2018	Biobeats	IQ Capital
$—2016-03-22	Spectral Edge	IQ Capital
$8M2016-02-02	Grapeshot	AlbionVC, IQ Capital
$2M2016	Biobeats	IQ Capital
$—2014	Biobeats	IQ Capital
$650K2013	Biobeats	ENIAC Ventures, IQ Capital
$21MUnknown date	Vsim	IQ Capital
$—Unknown date	Iotic	IQ Capital
$8MUnknown date	Foundries.io	IQ Capital

Funds3

Team

Co-investing

Investments